beta-D-GalNAc-(1->4)-[alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-Cer

Term ID

CHEBI:51013

Synonyms

(2S,3R,4E)-2-alkanamido-3-hydroxyoctadec-4-en-1-yl 2-acetamido-2-deoxy-beta-D-galactopyranosyl-(1->4)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranonosyl-(2->3)]-beta-D-galactopyranosyl-(1->4)-beta-D-glucopyranoside
(Gal)1 (GalNAc)1 (Glc)1 (Neu5Ac)1 (Cer)1
beta-D-GalNAc-(1->4)-[alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-Cer
ganglioside GM2
GM2
monosialoganglioside GM2
N-Acetyl-D-galactosaminyl-(N-acetylneuraminyl)-D-galactosyl-1,4-beta-D-glucosyl-N-acylsphingosine
N-Acetyl-D-galactosaminyl-(N-acetylneuraminyl)-D-galactosyl-D-glucosylceramide
Tay-Sachs ganglioside

Definition

A sialotriaosylceramide consisting of the tetrasaccharide β-D-GalNAc-(1→4)-[α-Neu5Ac-(2→3)]-β-D-Gal-(1→4)-β-D-Glc attached to the primary hydroxy function of ceramide.

References

kegg.compound:C04884
kegg.glycan:G00109
patent:WO0123431
pubmed:1371229
pubmed:15546874
pubmed:18207611
pubmed:19130519
pubmed:2457654
pubmed:2564593
pubmed:25867522
pubmed:26050638
pubmed:28416698
pubmed:2933632
pubmed:333030
pubmed:6210531
pubmed:6214725
pubmed:6225718
pubmed:7243492
pubmed:8250149

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from beta-D-GalNAc-(1->4)-[alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-Cer

Phenotype where environments contain beta-D-GalNAc-(1->4)-[alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-Cer

Phenotype modified by environments containing beta-D-GalNAc-(1->4)-[alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-Cer

Phenotype affecting beta-D-GalNAc-(1->4)-[alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-Cer

Human Disease Model